A
ALX Oncology
Clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway and enhance immune system response
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company dedicated to developing therapies that help patients combat cancer. The company focuses on blocking the CD47 checkpoint pathway to bridge the innate and adaptive immune systems. Its lead product candidate, evorpacept (ALX148), is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has shown promising clinical responses in both hematologic and solid malignancies when used in combination with leading anti-cancer agents. ALX Oncology operates in the biopharmaceutical market, primarily serving patients with various forms of cancer. The company generates revenue through the development and potential future commercialization of its therapeutic candidates.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
- Employees
- 63
- Open positions
- 7
- Dealroom signal
- 62.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Investment activity
- 1 company, latest Oct 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jan 2026 | $150M | — | OrbiMed · Redmile Group · venBio Partners · RA Capital Management | ↗ |
| POST IPO EQUITYOther financing | Oct 2023 | $63M | — | Lightstone Ventures · Ireland Strategic Investment Fund | ↗ |
Growth signals
Latest recorded traffic for ALX Oncology is 4.4K monthly website visits, down 15.4% over the last three months. ALX Oncology's team declined 3.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ALX Oncology in the South San Francisco ecosystem
The ALX Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
venBio Partners
Lightstone Ventures
Series B and later18 investors entered at this stage
BVF Partners
Vivo Capital
Cormorant Asset Management
Foresite CapitalJanus Henderson Investors
Silicon Valley Bank
Oxford Finance
Ireland Strategic Investment Fund
OrbiMed
Redmile Group
RA Capital Management
Marshall Wace
HBM Healthcare Investments
Blackstone
5AM Ventures
Driehaus Capital Management
TCGX- CCCoastlands Capital
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ALX Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ALX Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











